Ojha PK - Search Results

1

Assessment of superiority of HSP70-targeting aptamer-functionalized drug-nanocarrier over non-targeted commercially available counterpart in HCC therapy: in vitro and in vivo investigations and molecular modeling.

Chakraborty S, Chakraborty A, Mukherjee B, Besra SE, Dewanjee S, Mukherjee A, Sen R, Ojha PK, Kumar V, Shaw TK, Ghosh P, Debnath MC, Ghosh MK. Chakraborty S, et al. Among authors: ojha pk. Life Sci. 2023 Mar 15;317:121467. doi: 10.1016/j.lfs.2023.121467. Epub 2023 Feb 1. Life Sci. 2023. PMID: 36736764

2

Gangrenous cholecystitis due to kala-azar.

Singh UK, Ojha P, Suman S, Agrawal AK. Singh UK, et al. Ann Trop Paediatr. 1998 Sep;18(3):253-4. doi: 10.1080/02724936.1998.11747956. Ann Trop Paediatr. 1998. PMID: 9924565 No abstract available.

3

Diacerein-mediated inhibition of IL-6/IL-6R signaling induces apoptotic effects on breast cancer.

Bharti R, Dey G, Ojha PK, Rajput S, Jaganathan SK, Sen R, Mandal M. Bharti R, et al. Among authors: ojha pk. Oncogene. 2016 Jul 28;35(30):3965-75. doi: 10.1038/onc.2015.466. Epub 2015 Nov 30. Oncogene. 2016. PMID: 26616855

4

Therapeutic implication of 'Iturin A' for targeting MD-2/TLR4 complex to overcome angiogenesis and invasion.

Dey G, Bharti R, Ojha PK, Pal I, Rajesh Y, Banerjee I, Banik P, Parida S, Parekh A, Sen R, Mandal M. Dey G, et al. Among authors: ojha pk. Cell Signal. 2017 Jul;35:24-36. doi: 10.1016/j.cellsig.2017.03.017. Epub 2017 Mar 24. Cell Signal. 2017. PMID: 28347875

5

Exploring 2D-QSAR for prediction of beta-secretase 1 (BACE1) inhibitory activity against Alzheimer's disease.

Kumar V, Ojha PK, Saha A, Roy K. Kumar V, et al. Among authors: ojha pk. SAR QSAR Environ Res. 2020 Feb;31(2):87-133. doi: 10.1080/1062936X.2019.1695226. SAR QSAR Environ Res. 2020. PMID: 31865778

6

Aptamer-Functionalized Drug Nanocarrier Improves Hepatocellular Carcinoma toward Normal by Targeting Neoplastic Hepatocytes.

Chakraborty S, Dlie ZY, Chakraborty S, Roy S, Mukherjee B, Besra SE, Dewanjee S, Mukherjee A, Ojha PK, Kumar V, Sen R. Chakraborty S, et al. Among authors: ojha pk. Mol Ther Nucleic Acids. 2020 Jun 5;20:34-49. doi: 10.1016/j.omtn.2020.01.034. Epub 2020 Feb 5. Mol Ther Nucleic Acids. 2020. PMID: 32146417 Free PMC article.

7

Cheminformatic modelling of β-amyloid aggregation inhibitory activity against Alzheimer's disease.

Kumar V, Ojha PK, Saha A, Roy K. Kumar V, et al. Among authors: ojha pk. Comput Biol Med. 2020 Mar;118:103658. doi: 10.1016/j.compbiomed.2020.103658. Epub 2020 Feb 13. Comput Biol Med. 2020. PMID: 32174326

8

A Multi-layered Variable Selection Strategy for QSAR Modeling of Butyrylcholinesterase Inhibitors.

Kumar V, De P, Ojha PK, Saha A, Roy K. Kumar V, et al. Among authors: ojha pk. Curr Top Med Chem. 2020;20(18):1601-1627. doi: 10.2174/1568026620666200616142753. Curr Top Med Chem. 2020. PMID: 32543359

9

Recent advances in quantitative structure-activity relationship models of antimalarial drugs.

Ojha PK, Kumar V, Roy J, Roy K. Ojha PK, et al. Expert Opin Drug Discov. 2021 Jun;16(6):659-695. doi: 10.1080/17460441.2021.1866535. Epub 2021 Jan 11. Expert Opin Drug Discov. 2021. PMID: 33356651 Review.

10

Amalgamation of in-silico, in-vitro and in-vivo approach to establish glabridin as a potential CYP2E1 inhibitor.

Bhatt S, Kumar V, Dogra A, Ojha PK, Wazir P, Sangwan PL, Singh G, Nandi U. Bhatt S, et al. Among authors: ojha pk. Xenobiotica. 2021 Jun;51(6):625-635. doi: 10.1080/00498254.2021.1883769. Epub 2021 Feb 15. Xenobiotica. 2021. PMID: 33539218

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

69 results

Search Page

Filters